National Institute of Dental and Craniofacial Research (NIDCR)

91 total trials 11 currently recruiting 70 completed

National Institute of Dental and Craniofacial Research (NIDCR) sponsors 91 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 70 completed. 2 of these trials are in Phase 3-4 (later-stage) and 41 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sjogren's Syndrome, with 6 trials.

Trial Pipeline

91 total, page 1 of 2

RECRUITING Phase 1

Safety and Efficacy of PTH-IA

NCT07541209

RECRUITING Phase 2

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease

NCT07281456

RECRUITING

Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls

NCT03602599

RECRUITING

Natural History of Craniofacial Anomalies and Developmental Growth Variants

NCT02639312

RECRUITING

Characterization of Diseases With Salivary Gland Involvement

NCT02327884

RECRUITING

Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal

NCT01805869

RECRUITING

Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)

NCT01568697

RECRUITING

The Pathogenesis and Natural History of Sjogren's Disease

NCT01425892

RECRUITING Phase 1

Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

NCT00804154

RECRUITING

A Natural History Study of Bone and Mineral Disorders

NCT00024804

RECRUITING

Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome

NCT00001727

ACTIVE NOT RECRUITING Phase 1

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

NCT04496960

ACTIVE NOT RECRUITING Phase 2

Denosumab Treatment for Fibrous Dysplasia

NCT03571191

COMPLETED Phase 2

PTH-independent Effects of Encaleret

NCT05735015

COMPLETED Phase 2

Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

NCT05509595

COMPLETED Phase 2

Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia

NCT05419050

COMPLETED

Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions

NCT04348240

TERMINATED Phase 2

BGJ398 for the Treatment of Tumor-Induced Osteomalacia

NCT03510455

COMPLETED

Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population

NCT03327870

COMPLETED

Bacterial Arrangement on the Teeth

NCT01712672

TERMINATED Phase 1

Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)

NCT01748812

TERMINATED Phase 2

Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects

NCT01316770

COMPLETED Phase 1

Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma

NCT01195922

COMPLETED

The Molecular Anatomy of Oral Wound Healing

NCT01078467

TERMINATED

Collection of Tissue Specimens for Analysis and Establishment of Cell Cultures

NCT00802607

COMPLETED

Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome

NCT00565526

TERMINATED

Procurement of Tissue Samples for Cell Cultures and Analyses

NCT00435877

TERMINATED Phase 3

Effects of PTH Replacement on Bone in Hypoparathyroidism

NCT00395538

COMPLETED Phase 1

Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer

NCT00372320

COMPLETED

Physiologic Regulation of FGF-23

NCT00356512

TERMINATED Phase 2

Pilot Study of Raptiva to Treat Sjogren's Syndrome

NCT00344448

COMPLETED

Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal

NCT00316485

COMPLETED Phase 2

Dexamethasone to Treat Oral Lichen Planus

NCT00111072

COMPLETED

Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth

NCT00104026

COMPLETED Phase 2

Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus

NCT00102557

COMPLETED

Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations

NCT00100529

COMPLETED

Salivary Proteins in Disease and Health

NCT00100204

COMPLETED

Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia

NCT00099762

COMPLETED

Collection of Dental Plaque and Saliva for Studies of Bacterial Colonization of Teeth

NCT00098267

COMPLETED

Clinical Research Core Dental Screening Protocol

NCT00090818

COMPLETED

Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations

NCT00339339

COMPLETED Phase 2

Capsaicin to Control Pain Following Third Molar Extraction

NCT00088686

COMPLETED Phase 2

Synvisc to Treat Osteoarthritis of the Temporomandibular Joint

NCT00078351

COMPLETED Phase 2

Pain Pathways in the Brain

NCT00078364

COMPLETED Phase 2

Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction

NCT00078104

COMPLETED

Studying Phosphorus Metabolism

NCT00066183

COMPLETED Phase 1

Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients

NCT00055380

COMPLETED Phase 2

Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction

NCT00050362

COMPLETED

Study of Oral Bacteria in Patients With Dry Mouth

NCT00048685

COMPLETED Phase 2

Magnets in the Treatment of Sciatica

NCT00044109

Page 1 of 2 Next →

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 32
Phase 3 2

What the Pipeline for National Institute of Dental and Craniofacial Research (NIDCR) Shows

According to the ClinicalTrials.gov registry, National Institute of Dental and Craniofacial Research (NIDCR) is linked to 91 US clinical trials across every stage of research activity. Of those, 11 studies are currently recruiting, about 12% of the sponsor's indexed portfolio, and 70 are already marked complete, representing roughly 77% of the total.

The phase mix for National Institute of Dental and Craniofacial Research (NIDCR) reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 41 earlier-phase studies (Phase 1 and Phase 2).

The top therapeutic focus area indexed for National Institute of Dental and Craniofacial Research (NIDCR) is Sjogren's Syndrome with 6 linked trials, and 9 other condition areas appear in the top list above.

How to read these pipeline numbers

Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.